Eryk Latoch1, Jerzy Konstantynowicz2, Maryna Krawczuk-Rybak1, Anna Panasiuk3, Katarzyna Muszyńska-Rosłan1. 1. Department of Pediatric Oncology and Hematology, Medical University of Bialystok, Białystok, Poland. 2. Department of Pediatrics, Rheumatology, Immunology and Metabolic Bone Diseases, Medical University of Bialystok, University Children's Hospital 'Dr Ludwik Zamenhof', ul. Waszyngtona 17, 15-274, Białystok, Poland. jurekonstant@o2.pl. 3. Department of Pediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wrocław, Poland.
Abstract
Low bone mineral density (BMD) was diagnosed in 24% of childhood cancer survivors (CCS), whereas very low BMD was relatively uncommon at 8%. We suggest that low BMD in CCS may become alleviated over time. Stem cell transplantation, radiotherapy, and underweight were the strongest independent predictors of decreased BMD. PURPOSE: Childhood cancer survivors (CCS) are at risk of premature bone loss, although published studies are inconsistent. The objective of this study was to evaluate the prevalence and pattern of low bone mineral density (BMD) in short- and long-term CCS, and to determine clinical factors affecting skeleton after anticancer treatment. METHODS: This retrospective study was conducted in a cohort of 326 children and young adult CCS (147 females) who completed anticancer treatment. BMD was determined by dual-energy X-ray absorptiometry (DXA). Low BMD was defined as a Z-score ≤ - 1.0, and the very low BMD as a Z-score ≤ - 2.0. Additionally, the changes in BMD over time were studied in 123 CCS who had been re-examined by DXA during follow-up. RESULTS: Median age at diagnosis was 7.27 years (range, 4.4-10.6); median time between end of treatment and DXA was 6.12 (range, 4.0-22.0). Low BMD was found in 24% of CCS, while very low BMD was relatively uncommon (8%). Based on multivariate analysis, the following were significantly associated with low BMD at the follow-up: hematopoietic stem cell transplantation (OR 3.13, 95% CI 1.02-9.63), head and neck radiotherapy (OR 2.54, 95% CI 1.32-4.90), and body weight below the standard reference (OR 3.57, 95% CI 1.24-10.23). The time-related trajectory showed an improvement (BMDLS) or stabilization (BMDTB) in Z-scores values. CONCLUSION: These data based on serial DXA measurements, encompassing a long-lasting observation period, show that CCS may not be at risk of premature bone loss in young adulthood. However, it is unknown how the scenario for skeletal mass is until the CCS will achieve older or postmenopausal age.
Low bone mineral density (BMD) was diagnosed in 24% of childhood cancer survivors (CCS), whereas very low BMD was relatively uncommon at 8%. We suggest that low BMD in CCS may become alleviated over time. Stem cell transplantation, radiotherapy, and underweight were the strongest independent predictors of decreased BMD. PURPOSE: Childhood cancer survivors (CCS) are at risk of premature bone loss, although published studies are inconsistent. The objective of this study was to evaluate the prevalence and pattern of low bone mineral density (BMD) in short- and long-term CCS, and to determine clinical factors affecting skeleton after anticancer treatment. METHODS: This retrospective study was conducted in a cohort of 326 children and young adult CCS (147 females) who completed anticancer treatment. BMD was determined by dual-energy X-ray absorptiometry (DXA). Low BMD was defined as a Z-score ≤ - 1.0, and the very low BMD as a Z-score ≤ - 2.0. Additionally, the changes in BMD over time were studied in 123 CCS who had been re-examined by DXA during follow-up. RESULTS: Median age at diagnosis was 7.27 years (range, 4.4-10.6); median time between end of treatment and DXA was 6.12 (range, 4.0-22.0). Low BMD was found in 24% of CCS, while very low BMD was relatively uncommon (8%). Based on multivariate analysis, the following were significantly associated with low BMD at the follow-up: hematopoietic stem cell transplantation (OR 3.13, 95% CI 1.02-9.63), head and neck radiotherapy (OR 2.54, 95% CI 1.32-4.90), and body weight below the standard reference (OR 3.57, 95% CI 1.24-10.23). The time-related trajectory showed an improvement (BMDLS) or stabilization (BMDTB) in Z-scores values. CONCLUSION: These data based on serial DXA measurements, encompassing a long-lasting observation period, show that CCS may not be at risk of premature bone loss in young adulthood. However, it is unknown how the scenario for skeletal mass is until the CCS will achieve older or postmenopausal age.
Entities:
Keywords:
Bone mineral density; Late effects; Long-term survivors; Low bone mass; Short-term survivors
Authors: Catherine M Gordon; Babette S Zemel; Tishya A L Wren; Mary B Leonard; Laura K Bachrach; Frank Rauch; Vicente Gilsanz; Clifford J Rosen; Karen K Winer Journal: J Pediatr Date: 2016-11-03 Impact factor: 4.406
Authors: Hadley M Bloomhardt; Kyaw Sint; Wilhelmenia L Ross; Jaime Rotatori; Kathryn Ness; Cemre Robinson; Thomas O Carpenter; Eric J Chow; Nina S Kadan-Lottick Journal: Cancer Date: 2019-09-19 Impact factor: 6.860
Authors: Wassim Chemaitilly; Laurie E Cohen; Sogol Mostoufi-Moab; Briana C Patterson; Jill H Simmons; Lillian R Meacham; Hanneke M van Santen; Charles A Sklar Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Adam D G Baxter-Jones; Robert A Faulkner; Mark R Forwood; Robert L Mirwald; Donald A Bailey Journal: J Bone Miner Res Date: 2011-08 Impact factor: 6.741
Authors: J G Gurney; S C Kaste; W Liu; D K Srivastava; W Chemaitilly; K K Ness; J Q Lanctot; R P Ojha; K A Nottage; C L Wilson; Z Li; L L Robison; M M Hudson Journal: Pediatr Blood Cancer Date: 2014-02-28 Impact factor: 3.167
Authors: Sue C Kaste; Monika L Metzger; Anum Minhas; Zang Xiong; Shesh N Rai; Kirsten K Ness; Melissa M Hudson Journal: Pediatr Blood Cancer Date: 2009-04 Impact factor: 3.167
Authors: Karen Wasilewski-Masker; Sue C Kaste; Melissa M Hudson; Natia Esiashvili; Leonard A Mattano; Lillian R Meacham Journal: Pediatrics Date: 2008-03 Impact factor: 7.124
Authors: Jenneke E van Atteveld; Saskia M F Pluijm; Kirsten K Ness; Melissa M Hudson; Wassim Chemaitilly; Sue C Kaste; Leslie L Robison; Sebastian J C M M Neggers; Yutaka Yasui; Marry M van den Heuvel-Eibrink; Carmen L Wilson Journal: J Clin Oncol Date: 2019-05-31 Impact factor: 50.717
Authors: Jenneke E van Atteveld; Renée L Mulder; Marry M van den Heuvel-Eibrink; Melissa M Hudson; Leontien C M Kremer; Roderick Skinner; W Hamish Wallace; Louis S Constine; Claire E Higham; Sue C Kaste; Riitta Niinimäki; Sogol Mostoufi-Moab; Nathalie Alos; Danilo Fintini; Kimberly J Templeton; Leanne M Ward; Eva Frey; Roberto Franceschi; Vesna Pavasovic; Seth E Karol; Nadia L Amin; Lynda M Vrooman; Arja Harila-Saari; Charlotte Demoor-Goldschmidt; Robert D Murray; Edit Bardi; Maarten H Lequin; Maria Felicia Faienza; Olga Zaikova; Claire Berger; Stefano Mora; Kirsten K Ness; Sebastian J C M M Neggers; Saskia M F Pluijm; Jill H Simmons; Natascia Di Iorgi Journal: Lancet Diabetes Endocrinol Date: 2021-07-30 Impact factor: 44.867